title: [Prospective observational study of angiotensin converting enzyme inhibitors-induced hyperkalemia in hospitalized patients with chronic renal failure].
abstract: OBJECTIVE
  To study the incidence and risk factors of angiotensin converting enzyme inhibitors-induced hyperkalemia in hospitalized patients with hypertension and preexisting chronic renal failure.
  
  
  METHODS
  Two-months prospective observational study was used including all hospitalized patients older than 18 years with a history of hypertension, non-dialyzed chronic renal failure and who had angiotensin converting enzyme prescription at the time of the admission. Hyperkalemia greater than or equal to 5 mmol/L was detected in these patients. The studied variables were demographic, clinical, biological and therapeutic.
  
  
  RESULTS
  Eight patients, among 27 included, had a hyperkalemia (2963%). They were 73±15 years old. Factors that predispose to hyperkalemia were present in all patients. Hyperkalemia was associated in six cases with decompensation of renal function. The age was associated with hyperkalaemia in patients treated with angiotensin converting enzyme inhibitors (RC=1.21; IC95 1,11-1,46; P=0,021). Diabetes is a possible risk factor (OR=59 021 et, 95 0.93 to 2410, P=0.053). Compared with patients who did not develop hyperkalemia, the occurrence of hyperkalemia in patients included was associated with a longer duration of hospitalization (OR=130, 95 112 to 160, P=0. 022).
  
  
  CONCLUSIONS
  The prescription of angiotensin converting enzyme inhibitors in the elderly with chronic renal failure and diabetes requires careful monitoring of serum potassium.
authors.affiliation: Département de pharmacologie, faculté de médecine de Sfax, université de Sfax, 3029 Sfax, Tunisie. Lobna.ben-mahmoud@topnet.tn
authors.forename: Lobna
authors.initials: L
authors.lastname: Ben Mahmoud
authors.forename: Hanene
authors.initials: H
authors.lastname: Ghozzi
authors.forename: Khawla
authors.initials: K
authors.lastname: Kammoun
authors.forename: Ahmed
authors.initials: A
authors.lastname: Hakim
authors.forename: Mahmoud
authors.initials: M
authors.lastname: Kharrat
authors.forename: Mohamed
authors.initials: M
authors.lastname: Ben Hmida
authors.forename: Faical
authors.initials: F
authors.lastname: Jarraya
authors.forename: Zouheir
authors.initials: Z
authors.lastname: Sahnoun
authors.forename: Khaled
authors.initials: K
authors.lastname: Zeghal
authors.forename: Jamil
authors.initials: J
authors.lastname: Hachicha
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006760:Hospitalization; D006801:Humans; D006947:Hyperkalemia / Q000139:chemically induced* / Q000453:epidemiology; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D015994:Incidence; D007676:Kidney Failure, Chronic / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012307:Risk Factors
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors